See more : Cell MedX Corp. (CMXC) Income Statement Analysis – Financial Results
Complete financial analysis of NervGen Pharma Corp. (NGENF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NervGen Pharma Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sime Darby Plantation Berhad (SDPNF) Income Statement Analysis – Financial Results
- Gujarat Apollo Industries Limited (GUJAPOLLO.NS) Income Statement Analysis – Financial Results
- Bizlink Holding Inc. (3665.TW) Income Statement Analysis – Financial Results
- Hillman Solutions Corp. (HLMN) Income Statement Analysis – Financial Results
- PREMIER CAPITAL SERVICES LTD. (PREMCAP.BO) Income Statement Analysis – Financial Results
NervGen Pharma Corp. (NGENF)
About NervGen Pharma Corp.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 145.00K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 0.00 |
| Gross Profit | -145.00K | -115.11K | -42.63K | -39.65K | -38.22K | -19.76K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.05M | 16.61M | 6.87M | 6.16M | 6.45M | 780.40K | 0.00 |
| General & Administrative | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.73M | 6.34M | 5.94M | 5.03M | 3.38M | 578.08K | 11.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Cost & Expenses | 17.78M | 23.03M | 12.81M | 11.20M | 9.86M | 1.36M | 11.81K |
| Interest Income | 550.07K | 201.40K | 29.42K | 18.85K | 98.83K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 514.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 55.04K | 115.11K | 42.63K | 39.65K | 38.22K | 19.76K | 12.89K |
| EBITDA | -17.72M | -22.71M | -12.77M | -11.16M | -9.83M | -1.34M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.78M | -22.82M | -12.87M | -11.19M | -9.86M | -1.36M | -11.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.61M | 2.30M | 84.65K | 9.74K | 98.83K | 0.00 | 1.07K |
| Income Before Tax | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.60K | -84.65K | -9.74K | -133.64K | -141.38K | -12.89K |
| Net Income | -22.38M | -20.72M | -12.73M | -11.19M | -9.77M | -1.36M | -11.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.38 | -0.39 | -0.32 | -0.35 | -0.38 | -0.05 | 0.00 |
| EPS Diluted | -0.38 | -0.39 | -0.32 | -0.35 | -0.38 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
| Weighted Avg Shares Out (Dil) | 59.29M | 52.65M | 39.29M | 32.11M | 25.90M | 27.20M | 27.20M |
NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting...
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the...
NervGen Pharma Provides an Operational Update on Its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing...
NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease
Dr. Ksenia Kastanenka to Study NVG-291's Potential to Promote Repair in Alzheimer's Disease ModelsVancouver, British Columbia--(Newsfile Corp. - August 9, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to...
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating...
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that...
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board
NervGen Supports World Brain Day on July 22 to "Stop Multiple Sclerosis"Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative...
NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the...
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it...
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's DiseaseVancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions...
Source: https://incomestatements.info
Category: Stock Reports